Search Results

Your search for Benjamin Besse, MD, PhD, and Tony Mok, MD,Benjamin Besse, MD, PhD, and Tony Mok, MD matches 2 pages

Showing 1 - 2

By Benjamin Besse, MD, PhD, and Tony Mok, MD / 2015 European Cancer Congress

Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).

issues in oncology

By Caroline Helwick / November 15 2011

Predictive Biomarker for Bevacizumab: Are We Getting Closer?

The need to identify a biomarker to guide treatment with bevacizumab (Avastin) is abundantly clear, and studies presented at the 2011 European Multidisciplinary Cancer Congress suggest this goal may be in sight. “Finding predictive biomarkers is a challenge, but there are candidates,” said Eric Van ...

Apr

Today In Oncology

Search Results

Your search for Benjamin Besse, MD, PhD, and Tony Mok, MD,Benjamin Besse, MD, PhD, and Tony Mok, MD matches 2 pages

Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

Predictive Biomarker for Bevacizumab: Are We Getting Closer?

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer